In this episode, we invite Access Infinity Partner, Isabel Rubio back to the podcast to explore the unique challenges and innovative solutions reshaping market access and pricing within rare disease.

Isabel shares insights from her extensive experience with due diligence assessments in orphan drug development, discussing three transformative strategies that are revolutionising how companies prove value in ultra-rare diseases. From multi-domain endpoints and visual evidence to payment-by-results models, this episode reveals why traditional HTA frameworks fall short for orphan drugs and how early collaboration between pricing, market access, and clinical teams is essential for success.

Isabel has authored a blog on this topic, which you can read here: accessinfinity.com/blogs/breaking-through-barriers-how-innovation-is-revolutionising-orphan-drug-development.

Send us a text

In this insightful episode we speak with Lizzie Shanahan, Global Access AI Strategy Lead at Sanofi. With over six years' experience at Sanofi and a rich background in commercial roles, Lizzie shares her unique journey into the world of market access and how her diverse experience shapes her approach to launch excellence.

The conversation explores exciting developments in the industry, including the evolution of digital technologies and AI. Lizzie shares thoughtful insights on finding the right balance between technological innovation and maintaining essential human skills within the industry.

This is a great episode for professionals in market access or commercial leaders considering a career transition and provides both practical guidance and forward-thinking perspectives on the changing landscape of market access.

The opinions shared in this podcast are Lizzie's own views.

Send us a text

In this episode, we speak with Silvy Mardiguian, Senior Director and Head of HEOR for Europe & New Markets at BeiGene.

Silvy has been co-leading BeiGene’s preparedness and organisational readiness for the new Joint Clinical Assessment (JCA) framework, which is going to significantly change the EU HTA landscape.

Silvy shares key insights into some of the learnings and challenges she has encountered during this process and highlights why strong cross-functional collaboration has been key to making it all work.

We also hear about Silvy’s career journey to date — from her move from consulting into industry to the lessons she’s picked up along the way. She shares advice for anyone working in value and access, as well as some words of wisdom she’d give her younger self.

The opinions shared in this podcast are Silvy's own views.

Send us a text